Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
Elutia Inc. reported that it has issued a press release with preliminary financial results for the fourth quarter ended December 31, 2025. These preliminary figures are still subject to normal year-end accounting close and audit procedures, so final results may differ once the review is complete.
The company furnished the press release as an exhibit to the current report, making an early view of its quarter available while clarifying that this information is being provided for disclosure purposes and is not treated as formally filed under certain Exchange Act liability provisions.
Elutia Inc. director reports open-market share purchase
A director of Elutia Inc. (ELUT) reported buying Class A common stock in a personal capacity. On 12/17/2025, the reporting person purchased 12,500 shares of Elutia Class A common stock at a price of $0.51 per share. After this transaction, the director beneficially owned 31,098 shares of Class A common stock held directly.
Elutia Inc. director Brigid Makes reported an open-market purchase of Class A common stock. On 12/17/2025, the reporting person bought 25,000 Class A shares at a weighted average price of $0.52 per share, with individual trade prices ranging from $0.51 to $0.53. After this transaction, the director beneficially owns 27,000 Class A shares, held directly. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
Elutia Inc. insider C. Randal Mills, who serves as president, CEO, and director, reported buying additional company stock. On 12/17/2025, he acquired 3,000 shares of Elutia Class A common stock in an open-market purchase at $0.51 per share. Following this transaction, he directly beneficially owns 379,204 shares of the company’s Class A common stock.
Elutia Inc.'s Chief Financial Officer, Matthew Ferguson, reported buying additional company stock. On 12/17/2025, he purchased 60,000 shares of Elutia Inc. Class A common stock in an open market transaction coded as a purchase, at a weighted average price of $0.53 per share, with individual trade prices ranging from $0.51 to $0.54.
Following this transaction, Ferguson beneficially owns 447,110 shares of Elutia Inc. common stock, held directly. The filing notes that detailed breakdowns of the number of shares purchased at each separate price within the reported range are available upon request to the company, any security holder, or SEC staff.
Elutia Inc. director and 10% owner Kevin Rakin filed an amended insider ownership report describing an in-kind distribution of Class A common stock from HighCape investment entities on December 11, 2025.
On that date, HighCape Partners, L.P., HighCape Partners QP, L.P., HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC distributed all of their Elutia Class A shares to their partners and members pro rata, without payment of consideration. Rakin received 126,120 shares directly and his irrevocable trusts received 181,612 shares. The filing states that the distribution resulted in a change in the form of his beneficial ownership only.
Footnotes explain Rakin’s indirect holdings through multiple HighCape-affiliated entities and trusts, and the amendment corrects an earlier Form 4 that had misstated the number of shares distributed by the HighCape entities.
Elutia Inc. director and 10% owner Kevin Rakin reported a pro rata distribution of Class A common stock on 12/11/2025. HighCape investment entities distributed 4,372,497 shares of Elutia Class A stock to their partners and members without payment of consideration.
As part of this distribution, Rakin personally received 126,120 shares and his irrevocable trusts received 181,612 shares. Following the transaction, he beneficially owns 4,978,978 Elutia shares through various HighCape entities and trusts, and the distribution is described as being without payment of consideration and as a change in the form of his beneficial ownership only.
Elutia Inc. chief scientific officer Michelle LeRoux Williams reported routine equity compensation activity. On 12/10/2025, 12,500 restricted stock units converted into shares of Class A common stock, increasing her direct holdings. The company then withheld 3,951 shares at $ 0.7 per share to cover tax obligations, leaving her with 101,934 Class A shares held directly and 50,000 restricted stock units outstanding.
These vested units are part of a 150,000 restricted stock unit grant dated 01/31/2024, which vests in scheduled installments from 06/10/2024 through 12/10/2026.
Elutia Inc.'s chief financial officer Matthew Ferguson reported equity awards activity on December 10, 2025. He acquired 12,500 shares of Class A common stock upon vesting of restricted stock units, with 4,461 shares withheld by the company to satisfy tax withholding requirements.
After these transactions, Ferguson directly owned 387,110 shares of Elutia Class A common stock and held 50,000 restricted stock units as derivative securities. The vested units are part of a 150,000-unit restricted stock grant awarded on January 31, 2024 that vests as to 1/6 on June 10, 2024 and as to 1/12 quarterly through December 10, 2026.
Elutia Inc. President, CEO and director C. Randal Mills reported the vesting of 27,083 restricted stock units into shares of the company’s Class A common stock on December 10, 2025. After this transaction, he directly owned 376,204 Class A shares and 270,833 restricted stock units.
Of the shares delivered at vesting, 9,664 shares were withheld by Elutia to satisfy tax withholding requirements, with the remaining shares retained by Mills. The filing notes that these units are part of a 487,500‑unit restricted stock grant awarded on January 31, 2024, which vests over time and upon the stock reaching price targets of $6.00, $10.00, $14.00 and $18.00 for twenty consecutive trading days, subject to his continued employment and the company’s trading‑window restrictions.